Rothschild & Co Redburn initiated coverage of Repligen (RGEN) with a Buy rating and $160 price target The firm says Repligen is a pure-play bioprocessing company and leader in continuous manufacturing. The stock’s premium valuation is warranted given the company’s “sector-leading” mid-term revenue and adjusted earnings outlooks of 15% and 29% respectively, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen price target lowered to $145 from $175 at Barclays
- Repligen price target lowered to $140 from $170 at Evercore ISI
- Repligen: Strong Execution, Innovation, and Cross‑Selling Momentum Support Sustained Growth and Reaffirmed Buy Rating
- Repligen price target raised to $208 from $180 at H.C. Wainwright
- Repligen price target lowered to $195 from $200 at UBS